Johnson & Johnson (JNJ) Exceeds First-quarter Earnings Projections

Johnson & Johnson (JNJ) surpassed its first-quarter earnings forecasts, reporting revenue of $24.1 billion and adjusted earnings per share of $2.70. This success was driven by strong sales of Darzalex and Tremfya, which offset a decline in Stelara sales due to patent expiration. The company also raised its full-year sales and EPS guidance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin